Chugai Pharmaceutical (4519) Stock Overview
Engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
4519 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Chugai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥6,391.00 |
| 52 Week High | JP¥8,655.00 |
| 52 Week Low | JP¥5,942.00 |
| Beta | 0.69 |
| 1 Month Change | -13.97% |
| 3 Month Change | -15.91% |
| 1 Year Change | -12.87% |
| 3 Year Change | 77.09% |
| 5 Year Change | 36.62% |
| Change since IPO | 1,421.67% |
Recent News & Updates
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit
Aug 17
Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 26If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity
Jul 10Recent updates
Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Shareholders Might Be Looking For Exit
Aug 17Chugai Pharmaceutical Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Jul 26If EPS Growth Is Important To You, Chugai Pharmaceutical (TSE:4519) Presents An Opportunity
Jul 10Chugai Pharmaceutical's (TSE:4519) Upcoming Dividend Will Be Larger Than Last Year's
Jun 10Chugai Pharmaceutical (TSE:4519) Is Paying Out A Larger Dividend Than Last Year
May 21Chugai Pharmaceutical Co., Ltd. Just Recorded A 19% EPS Beat: Here's What Analysts Are Forecasting Next
Apr 27Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Business Is Yet to Catch Up With Its Share Price
Apr 25Calculating The Intrinsic Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Mar 17
Accelerating RED Capabilities And Robust Pipeline Will Enhance Future Prospects
Emphasis on RED capabilities and innovative products aims to drive revenue growth and improve net and operating margins.Chugai Pharmaceutical Co., Ltd. (TSE:4519) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
Feb 03Chugai Pharmaceutical Co., Ltd.'s (TSE:4519) Share Price Could Signal Some Risk
Dec 23Calculating The Fair Value Of Chugai Pharmaceutical Co., Ltd. (TSE:4519)
Dec 05Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 30Chugai Pharmaceutical Co., Ltd. Just Beat Revenue By 12%: Here's What Analysts Think Will Happen Next
Oct 29Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Oct 15Should You Be Adding Chugai Pharmaceutical (TSE:4519) To Your Watchlist Today?
Oct 12Chugai Pharmaceutical's (TSE:4519) Dividend Will Be ¥41.00
Sep 24Shareholder Returns
| 4519 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -0.7% | -5.3% | -1.4% |
| 1Y | -12.9% | -15.9% | 14.1% |
Return vs Industry: 4519 exceeded the JP Pharmaceuticals industry which returned -15.9% over the past year.
Return vs Market: 4519 underperformed the JP Market which returned 14.1% over the past year.
Price Volatility
| 4519 volatility | |
|---|---|
| 4519 Average Weekly Movement | 6.4% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in JP Market | 7.5% |
| 10% least volatile stocks in JP Market | 1.7% |
Stable Share Price: 4519's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4519's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1925 | 5,026 | Osamu Okuda | www.chugai-pharm.co.jp |
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE.
Chugai Pharmaceutical Co., Ltd. Fundamentals Summary
| 4519 fundamental statistics | |
|---|---|
| Market cap | JP¥9.89t |
| Earnings (TTM) | JP¥395.44b |
| Revenue (TTM) | JP¥1.20t |
Is 4519 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4519 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.20t |
| Cost of Revenue | JP¥354.41b |
| Gross Profit | JP¥841.80b |
| Other Expenses | JP¥446.36b |
| Earnings | JP¥395.44b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Oct 24, 2025
| Earnings per share (EPS) | 240.29 |
| Gross Margin | 70.37% |
| Net Profit Margin | 33.06% |
| Debt/Equity Ratio | 0% |
How did 4519 perform over the long term?
See historical performance and comparisonDividends
Does 4519 pay a reliable dividends?
See 4519 dividend history and benchmarks| Chugai Pharmaceutical dividend dates | |
|---|---|
| Ex Dividend Date | Jun 27 2025 |
| Dividend Pay Date | Aug 28 2025 |
| Days until Ex dividend | 62 days |
| Days until Dividend pay date | 0 days |
Does 4519 pay a reliable dividends?
See 4519 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/08/27 13:35 |
| End of Day Share Price | 2025/08/27 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chugai Pharmaceutical Co., Ltd. is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Siti Bte Salikin | CFRA Equity Research |